RU2761041C2 - Парентеральный жидкий препарат, включающий карбаматное соединение - Google Patents
Парентеральный жидкий препарат, включающий карбаматное соединение Download PDFInfo
- Publication number
- RU2761041C2 RU2761041C2 RU2019121911A RU2019121911A RU2761041C2 RU 2761041 C2 RU2761041 C2 RU 2761041C2 RU 2019121911 A RU2019121911 A RU 2019121911A RU 2019121911 A RU2019121911 A RU 2019121911A RU 2761041 C2 RU2761041 C2 RU 2761041C2
- Authority
- RU
- Russia
- Prior art keywords
- cyclodextrin
- formula
- liquid composition
- parenteral liquid
- carbamate compound
- Prior art date
Links
- -1 carbamate compound Chemical class 0.000 title claims abstract 10
- 239000007788 liquid Substances 0.000 title claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 10
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000004480 active ingredient Substances 0.000 claims abstract 5
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims abstract 4
- 230000001773 anti-convulsant effect Effects 0.000 claims abstract 3
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract 3
- 229960003965 antiepileptics Drugs 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 3
- 150000002367 halogens Chemical class 0.000 claims abstract 3
- 150000002431 hydrogen Chemical class 0.000 claims abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 238000002347 injection Methods 0.000 claims abstract 3
- 239000007924 injection Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000002904 solvent Substances 0.000 claims abstract 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- KWBIXTIBYFUAGV-UHFFFAOYSA-N ethylcarbamic acid Chemical compound CCNC(O)=O KWBIXTIBYFUAGV-UHFFFAOYSA-N 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160170389 | 2016-12-14 | ||
| KR10-2016-0170389 | 2016-12-14 | ||
| PCT/KR2017/014727 WO2018111000A1 (ko) | 2016-12-14 | 2017-12-14 | 카바메이트 화합물을 포함하는 비경구용 액상 제제 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019121911A RU2019121911A (ru) | 2021-01-15 |
| RU2019121911A3 RU2019121911A3 (enExample) | 2021-03-05 |
| RU2761041C2 true RU2761041C2 (ru) | 2021-12-02 |
Family
ID=62559693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121911A RU2761041C2 (ru) | 2016-12-14 | 2017-12-14 | Парентеральный жидкий препарат, включающий карбаматное соединение |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12070447B2 (enExample) |
| EP (1) | EP3556349B1 (enExample) |
| JP (1) | JP7110196B2 (enExample) |
| KR (1) | KR102605030B1 (enExample) |
| CN (2) | CN118766839A (enExample) |
| AU (1) | AU2017374450B2 (enExample) |
| CL (1) | CL2019001617A1 (enExample) |
| DK (1) | DK3556349T3 (enExample) |
| ES (1) | ES2901427T3 (enExample) |
| IL (1) | IL267192B2 (enExample) |
| MX (1) | MX390841B (enExample) |
| MY (1) | MY200159A (enExample) |
| PL (1) | PL3556349T3 (enExample) |
| PT (1) | PT3556349T (enExample) |
| RU (1) | RU2761041C2 (enExample) |
| WO (1) | WO2018111000A1 (enExample) |
| ZA (1) | ZA201903748B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3711758T3 (fi) | 2017-11-14 | 2024-05-13 | Sk Biopharmaceuticals Co Ltd | Karbamaattiyhdisteen käyttö poissaolokohtauksen tai poissaolokohtausepilepsian ehkäisemiseksi, lievittämiseksi tai hoitamiseksi |
| MX2021003203A (es) * | 2018-09-21 | 2021-05-27 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico. |
| EP3854392A4 (en) * | 2018-09-21 | 2022-08-17 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060258718A1 (en) * | 2005-04-22 | 2006-11-16 | Choi Yong M | Neurotherapeutic azole compounds |
| US20140080812A1 (en) * | 2005-09-30 | 2014-03-20 | Lundbeck Llc | Novel parenteral carbamazepine formulation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101309691A (zh) * | 2005-09-30 | 2008-11-19 | 奥瓦什医药品公司 | 新的胃肠外的卡马西平制剂 |
| CN101578103B (zh) * | 2006-06-29 | 2013-09-25 | 林科杰诺米克斯株式会社 | 抗生素的注射剂及其给予液 |
| US8343995B2 (en) * | 2007-04-27 | 2013-01-01 | Cydex Pharmaceuticals, Inc. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
| BRPI0924997B1 (pt) | 2009-06-22 | 2024-01-16 | Sk Biopharmaceuticals Co., Ltd | Método para preparar um composto de éster do ácido 1-aril-2- tetrazoil etil carbâmico |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
-
2017
- 2017-12-14 US US16/468,756 patent/US12070447B2/en active Active
- 2017-12-14 DK DK17880335.9T patent/DK3556349T3/da active
- 2017-12-14 KR KR1020197018404A patent/KR102605030B1/ko active Active
- 2017-12-14 MX MX2019006939A patent/MX390841B/es unknown
- 2017-12-14 ES ES17880335T patent/ES2901427T3/es active Active
- 2017-12-14 PL PL17880335T patent/PL3556349T3/pl unknown
- 2017-12-14 WO PCT/KR2017/014727 patent/WO2018111000A1/ko not_active Ceased
- 2017-12-14 JP JP2019531627A patent/JP7110196B2/ja active Active
- 2017-12-14 CN CN202410768574.7A patent/CN118766839A/zh active Pending
- 2017-12-14 AU AU2017374450A patent/AU2017374450B2/en active Active
- 2017-12-14 CN CN201780077651.2A patent/CN110267647A/zh active Pending
- 2017-12-14 RU RU2019121911A patent/RU2761041C2/ru active
- 2017-12-14 PT PT178803359T patent/PT3556349T/pt unknown
- 2017-12-14 MY MYPI2019003346A patent/MY200159A/en unknown
- 2017-12-14 EP EP17880335.9A patent/EP3556349B1/en active Active
-
2019
- 2019-06-10 IL IL267192A patent/IL267192B2/en unknown
- 2019-06-11 ZA ZA2019/03748A patent/ZA201903748B/en unknown
- 2019-06-12 CL CL2019001617A patent/CL2019001617A1/es unknown
-
2024
- 2024-07-22 US US18/779,456 patent/US20240374568A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060258718A1 (en) * | 2005-04-22 | 2006-11-16 | Choi Yong M | Neurotherapeutic azole compounds |
| US20140080812A1 (en) * | 2005-09-30 | 2014-03-20 | Lundbeck Llc | Novel parenteral carbamazepine formulation |
Non-Patent Citations (5)
| Title |
|---|
| ARUN R. et al. Cyclodextrins as Drug Carrier Molecule: A Review // Sci Pharm. 2008. Vol. 76, P. 567-598. * |
| DEL VALLE E.M.M. Cyclodextrins and their uses: a review // Process Biochemistry. 2004. Vol. 39(9), P. 1033-1046. * |
| DEL VALLE E.M.M. Cyclodextrins and their uses: a review // Process Biochemistry. 2004. Vol. 39(9), P. 1033-1046. ПЕРЦЕВ И.М. Фармацевтические и медико-биологические аспекты лекарств: в 2 т. Т. 1. - Харьков: УкрФА. 1999. - 464 с. МАШКОВСКИЙ М.Д. Лекарственные средства. - 16-е изд., перераб., испр. и доп. - М.: Новая волна, 2012. - 1216 с. ARUN R. et al. Cyclodextrins as Drug Carrier Molecule: A Review // Sci Pharm. 2008. Vol. 76, P. 567-598. * |
| МАШКОВСКИЙ М.Д. Лекарственные средства. - 16-е изд., перераб., испр. и доп. - М.: Новая волна, 2012. - 1216 с. * |
| ПЕРЦЕВ И.М. Фармацевтические и медико-биологические аспекты лекарств: в 2 т. Т. 1. - Харьков: УкрФА. 1999. - 464 с. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118766839A (zh) | 2024-10-15 |
| RU2019121911A (ru) | 2021-01-15 |
| BR112019011914A2 (pt) | 2019-11-05 |
| CL2019001617A1 (es) | 2019-08-23 |
| JP2020502108A (ja) | 2020-01-23 |
| IL267192B2 (en) | 2023-05-01 |
| IL267192A (enExample) | 2019-07-31 |
| RU2019121911A3 (enExample) | 2021-03-05 |
| AU2017374450B2 (en) | 2023-05-11 |
| WO2018111000A1 (ko) | 2018-06-21 |
| US12070447B2 (en) | 2024-08-27 |
| MY200159A (en) | 2023-12-09 |
| JP7110196B2 (ja) | 2022-08-01 |
| KR102605030B1 (ko) | 2023-11-23 |
| MX390841B (es) | 2025-03-21 |
| CN110267647A (zh) | 2019-09-20 |
| PL3556349T3 (pl) | 2022-04-11 |
| IL267192B1 (en) | 2023-01-01 |
| PT3556349T (pt) | 2021-12-28 |
| US20240374568A1 (en) | 2024-11-14 |
| EP3556349A4 (en) | 2020-07-01 |
| ES2901427T3 (es) | 2022-03-22 |
| AU2017374450A1 (en) | 2019-07-04 |
| EP3556349A1 (en) | 2019-10-23 |
| DK3556349T3 (da) | 2022-01-03 |
| ZA201903748B (en) | 2020-12-23 |
| KR20190087568A (ko) | 2019-07-24 |
| US20190314336A1 (en) | 2019-10-17 |
| EP3556349B1 (en) | 2021-11-24 |
| CA3046458A1 (en) | 2018-06-21 |
| MX2019006939A (es) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4334229B2 (ja) | プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤 | |
| US20240374568A1 (en) | Parenteral liquid preparation comprising carbamate compound | |
| KR102433489B1 (ko) | 눈의 후안부로의 약물 전달을 위한 안구용 제제 | |
| KR101747476B1 (ko) | 마취 제제 | |
| PT1501496E (pt) | Formulações contendo amiodarona e éter sulfoalquílico de ciclodextrina | |
| JP2010508372A (ja) | ピモベンダン及びシクロデキストリンの錯体を含む液体製剤 | |
| CN113271923A (zh) | 呋塞米的药物组合物及其用途 | |
| CN1505513A (zh) | 注射用西洛他唑水性制剂 | |
| EP3906020B1 (en) | Pharmaceutical compositions of torsemide and their uses | |
| JP2009504634A (ja) | プロポフォールを含む水性麻酔剤組成物 | |
| CA3046458C (en) | Parenteral liquid preparation comprising carbamate compound | |
| HK40110938A (zh) | 包含氨基甲酸酯化合物的肠胃外液体制剂 | |
| TW202304426A (zh) | 用於注射之包含１－（５－（２，４－二氟苯基）－１－（（３－氟苯基）磺醯基）－４－甲氧基－１ｈ－吡咯－３－基）－ｎ－甲基甲胺的新調配物 | |
| HK40015062A (en) | Parenteral liquid preparation comprising carbamate compound | |
| BR112019011914B1 (pt) | Formulação líquida parenteral, composição injetável, e, método para preparar uma formulação líquida parenteral | |
| HK40040553A (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| HK40040553B (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| HK1064056B (en) | An aqueous pharmaceutical preparation of cilostazol for parenteral use |